March, 2024, Kyiv, Ukraine. Enamine Ltd, the global leader in supplying small molecules and early drug discovery services, announces the expansion of its library synthesis capabilities with a focus on Enamine REAL compounds to further support the growing demands of agricultural and pharmaceutical companies, research institutes, and drug discovery centers.
Enamine REAL (REadily AccessibLe) universe stands at the forefront of drug discovery, housing over 2.7 trillion meticulously curated molecules that are synthesized with over 80% success rate within 3-4 weeks. This expansive resource facilitates compliable virtual screening and analog searches and significantly boosts the hit discovery and expansion processes making it an indispensable tool for the global research community. Understanding the crucial role of fast delivery of the ready-to-screen REAL molecules, Enamine announces a 25% expansion of its Parallel Chemistry Department with an experimentation throughput of up to 40,000 compounds per month. This has been achieved by team expansion, adjusting the shifts, and workflow optimization.
Yurii Moroz, Ph.D., Vice President of Sales and Marketing at Enamine, commented: This strategic growth is aimed at accelerating research processes and meeting the demands of clients more swiftly. The expansion reinforces Enamine’s commitment to providing top-notch service and cutting-edge solutions in the fast-paced world of drug discovery.
Dmytro Radchenko, Ph.D., Head of Parallel Chemistry at Enamine, added: Our primary focus remains dedicated to delivering novel compounds, refining our methodologies, and consistently expanding borders of synthetically accessible chemical space.
